$599
Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i

Alnylam 2023 Pipeline Updates; Pfizer Full-Year 2024 Guidance Call; Zepbound Available Through Ro Body Program; Novo Challenges IRA’s Constitutional Legitimacy; Tandem Source Full Launch in US

A series of cardiometabolic-related news items have been observed from Alnylam, Roche, Ro, Novo Nordisk, and Tandem. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home